Astrazeneca (AZN) EPS (Diluted) (QoQ) (2009 - 2026)
Astrazeneca (AZN) EPS (Diluted) (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,341,257,560.14% |
| Dec 31, 2025 | -100.00% |
| Sep 30, 2025 | 12,148,252.94% |
| Jun 30, 2025 | -100.00% |
| Mar 31, 2025 | 222,644,261.70% |
| Dec 31, 2024 | -100.00% |
| Sep 30, 2024 | 2,843,633,601.28% |
| Jun 30, 2024 | -100.00% |
| Mar 31, 2024 | 135,536,075.79% |
| Dec 31, 2023 | -100.00% |
| Sep 30, 2023 | 5,379,474,813.78% |
| Jun 30, 2023 | -100.00% |
| Mar 31, 2023 | 171,324,021.82% |
| Dec 31, 2022 | -100.00% |
| Sep 30, 2022 | 4,276,810,812.11% |
| Jun 30, 2022 | -100.05% |
| Mar 31, 2022 | 309,569.88% |
| Dec 31, 2021 | 100.00% |
| Sep 30, 2021 | -180,181,818,181,818,272.00% |
| Jun 30, 2021 | -100.00% |